All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Neutralization of lenvatinib charge hampers encapsulation into ferritin nanocages

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F19%3A43917156" target="_blank" >RIV/62156489:43210/19:43917156 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11310/19:10422997 RIV/00216208:11320/19:10422997

  • Result on the web

    <a href="https://mnet.mendelu.cz/mendelnet2019/mnet_2019_full.pdf" target="_blank" >https://mnet.mendelu.cz/mendelnet2019/mnet_2019_full.pdf</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Neutralization of lenvatinib charge hampers encapsulation into ferritin nanocages

  • Original language description

    Lenvatinib is an oral multi-target tyrosine-kinase (TK) inhibitor. Ferritins are proteins naturally occurring in human body, where they are responsible for the iron storage, transport and harmful ferrous species detoxification. The ferric-ions-free apo-form of ferritins can be used for drug encapsulation and delivery to tumor cells. To avoid harmful side effects and increase the anticancer efficiency, we investigated to prepare lenvatinib-loaded apoferritin (ApoLen) nanoparticles. We tested various experimental conditions, i.e. different lenvatinib solvents and pH. Nevertheless, the construction of ApoLen nanoparticles was not successful. Therefore, lenvatinib interactions with the apoferritin cavity as well as lenvatinib encapsulation into the ApoLen nanoparticles were studied in silico using molecular dynamics (MD) simulations. In accordance with experimental results, theoretical models demonstrated that lenvatinib molecules are not suitable for preparation of ApoLen nanoparticles.

  • Czech name

  • Czech description

Classification

  • Type

    D - Article in proceedings

  • CEP classification

  • OECD FORD branch

    30107 - Medicinal chemistry

Result continuities

  • Project

    <a href="/en/project/GA18-10251S" target="_blank" >GA18-10251S: Comprehensive insight into mechanisms of action and metabolism of tyrosine kinase inhibitors and a study of ways increasing their antitumor efficiency</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2019

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Article name in the collection

    MendelNet 2019: Proceedings of International PhD Students Conference

  • ISBN

    978-80-7509-688-3

  • ISSN

  • e-ISSN

  • Number of pages

    6

  • Pages from-to

    665-670

  • Publisher name

    Mendelova univerzita v Brně

  • Place of publication

    Brno

  • Event location

    Brno

  • Event date

    Nov 6, 2019

  • Type of event by nationality

    WRD - Celosvětová akce

  • UT code for WoS article

    000576735500120